Study: New peptide probes could help detect disease faster

A new advancement in real-time visualization of body tissues using molecular imaging probes could significantly increase early detection and treatment capabilities of cancer and other diseases, according to results of a study published online in Nature Communications.

European researchers developed the technique—which employs probes made of peptide molecules and a newly designed fluorescent tag to track and observe target cell processes—using fungal cells, though the technique is applicable to tissues collected from patient samples.

"Peptides are a powerful tool for spotting small signs of disease but until now we did not have a good way of tracking them,” Marc Vendrell, MD, of the University of Edinburgh MRC Centre for Inflammation Research, told Phys.org. “With this new technology, we can make probes to detect diseases with more accuracy and at earlier stages."

Using the new peptide probes allowed researchers to detect minute molecular changes in tissues and track them in real-time, potentially leading to much earlier disease diagnosis and the ability to evaluate the effectiveness of subsequent treatments.

The new technique could eventually help improve diagnostic imaging procedures such as PET scans to catch disease faster and further enhance early detection capabilities, the researchers said.

John Hocter,

Digital Editor

With nearly a decade of experience in print and digital publishing, John serves as Content Marketing Manager. His professional skill set includes feature writing, content marketing and social media strategy. A graduate of The Ohio State University, John enjoys spending time with his wife and daughter, along with a number of surprisingly mischievous indoor cacti.

Around the web

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.